Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives

A new class of 4-aminoquinoline derivatives based on the natural product isatin scaffold were designed and synthesized for biological evaluation against three strains of the malaria parasite Plasmodium falciparum. These derivatives showed anti-plasmodial IC50 values in the ranges of 1.3–0.079 and 2.0–0.050 μM against a chloroquine-sensitive (D10) and two resistant (K1 and W2) strains of P. falciparum, respectively. In order to determine potential targets for this class of compounds in P. falciparum, selected compounds were also tested against the parasitic cysteine protease falcipain-2. In terms of further development of this class of isatin derivatives, two of the compounds based on a flexible alkyl chain linker and a thiosemicarbazone moiety warrant further investigation as potential anti-plasmodial leads. These two derivatives showed good in vitro activity against K1 and W2 with IC50 values of 51 and 54 nM, respectively, while retaining potency against the D10 strain with IC50 values of 79 and 95 nM, respectively. Generally speaking, the inhibitory potency of all compounds in the series against the parasites did not strongly correlate with inhibitory potency against falcipain-2 for selected compounds tested, which at best was weak to moderate, suggesting other mechanisms of inhibition may also be involved or compounds may be selectively taken up by Plasmodium falciparum.

A new series of 4-aminoquinoline isatin derivatives were synthesized and screened for in vitro anti-plasmodial activity and inhibition of falcipain-2. These compounds showed IC50 values in the range of 0.05–2 μM against drug resistant and sensitive strains of P. falciparum.Figure optionsDownload as PowerPoint slide